{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:15:00Z","timestamp":1777860900923,"version":"3.51.4"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26460221"],"award-info":[{"award-number":["26460221"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23590642"],"award-info":[{"award-number":["23590642"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26460629"],"award-info":[{"award-number":["26460629"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20 K07066"],"award-info":[{"award-number":["20 K07066"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04010"],"award-info":[{"award-number":["17H04010"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21 K06596"],"award-info":[{"award-number":["21 K06596"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["DNW-14022"],"award-info":[{"award-number":["DNW-14022"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.addr.2022.114617","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T20:54:12Z","timestamp":1667854452000},"page":"114617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Cyclodextrins applied to the treatment of lysosomal storage disorders"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-4469","authenticated-orcid":false,"given":"Yoichi","family":"Ishitsuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsumi","family":"Irie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneaki","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114617_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183336","article-title":"Inherited disorders of lysosomal membrane transporters","volume":"1862","author":"Huizing","year":"2020","journal-title":"Biochim. Biophys. Acta, Biomembr."},{"key":"10.1016\/j.addr.2022.114617_b0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jimd.12131","article-title":"Treating lysosomal storage disorders: What have we learnt?","volume":"43","author":"Lachmann","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry Disease: The Current Treatment Landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs."},{"key":"10.1016\/j.addr.2022.114617_b0020","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"COMET Investigator Group, Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.addr.2022.114617_b0025","doi-asserted-by":"crossref","unstructured":"B.K. Burton, M. Balwani, F. Feillet, I. Bari\u0107, T.A. Burrow, C. Camarena Grande, M. Coker, A. Consuelo-S\u00e1nchez, P. Deegan, M. Di Rocco, G.M. Enns, R. Erbe, F. Ezgu, C. Ficicioglu, K.N. Furuya, J. Kane, C. Laukaitis, E. Mengel, E.G. Neilan, S. Nightingale, H. Peters, M. Scarpa, K.O. Schwab, V. Smolka, V. Valayannopoulos, M. Wood, Z. Goodman, Y. Yang, S. Eckert, S. Rojas-Caro, A.G. Quinn, A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency, N Engl J Med. 373 (2015) 1010\u20131020. 10.1056\/NEJMoa1501365.","DOI":"10.1056\/NEJMoa1501365"},{"key":"10.1016\/j.addr.2022.114617_b0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2022.114617_b0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0040","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","article-title":"Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial","volume":"37","author":"Schweighardt","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2022.114617_b0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","article-title":"Galsulfase (Naglazyme\u00ae) therapy in infants with mucopolysaccharidosis VI","volume":"37","author":"Harmatz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ymgme.2020.06.010","article-title":"Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment","volume":"131","author":"Thurberg","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0055","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41436-021-01156-3","article-title":"One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency","volume":"23","author":"Diaz","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.addr.2022.114617_b0060","doi-asserted-by":"crossref","first-page":"12870","DOI":"10.3390\/ijms222312870","article-title":"Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective","volume":"22","author":"Pinto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114464","article-title":"Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders","volume":"188","author":"Del Grosso","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114617_b0070","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1523\/JNEUROSCI.1317-11.2011","article-title":"Unesterified cholesterol accumulation in late endosomes\/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment","volume":"31","author":"Aqul","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2022.114617_b0075","first-page":"81","article-title":"Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease","volume":"1","author":"Ko","year":"2005","journal-title":"PLoS Genet."},{"key":"10.1016\/j.addr.2022.114617_b0080","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1017\/S146239940800080X","article-title":"The pathogenesis of Niemann-Pick type C disease: a role for autophagy?","volume":"10","author":"Pacheco","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.addr.2022.114617_b0085","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.stemcr.2014.03.014","article-title":"Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells","volume":"2","author":"Maetzel","year":"2014","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.addr.2022.114617_b0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-5-16","article-title":"Niemann-Pick disease type C","volume":"5","author":"Vanier","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.addr.2022.114617_b0095","doi-asserted-by":"crossref","first-page":"19316","DOI":"10.1073\/pnas.0910916106","article-title":"Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells","volume":"106","author":"Abi-Mosleh","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.addr.2022.114617_b0100","doi-asserted-by":"crossref","first-page":"e6951","DOI":"10.1371\/journal.pone.0006951","article-title":"Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression","volume":"4","author":"Davidson","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114617_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105469","article-title":"Glial contribution to cyclodextrin-mediated reversal of cholesterol accumulation in murine NPC1-deficient neurons in vivo","volume":"158","author":"Barthelemy","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0110","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1073\/pnas.0914309107","article-title":"Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells","volume":"107","author":"Rosenbaum","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.addr.2022.114617_b0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2012.11.005","article-title":"Effects of cyclodextrin in two patients with Niemann-Pick Type C disease","volume":"108","author":"Matsuo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.arcmed.2014.11.020","article-title":"Cyclodextrins, blood-brain barrier, and treatment of neurological diseases","volume":"45","author":"Vecserny\u00e9s","year":"2014","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.addr.2022.114617_b0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymgme.2013.04.003","article-title":"Lung toxicity of hydroxypropyl-\u03b2-cyclodextrin infusion","volume":"109","author":"Chien","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/js960213f","article-title":"Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation","volume":"86","author":"Irie","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0135","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0192623312441405","article-title":"Long-term parenteral administration of 2-hydroxypropyl-\u03b2-cyclodextrin causes bone loss","volume":"40","author":"Kantner","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.addr.2022.114617_b0140","doi-asserted-by":"crossref","first-page":"276ra26","DOI":"10.1126\/scitranslmed.3010101","article-title":"Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease","volume":"7","author":"Vite","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2022.114617_b0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1203\/PDR.0b013e3181df4623","article-title":"2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease","volume":"68","author":"Ward","year":"2010","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2022.114617_b0150","doi-asserted-by":"crossref","first-page":"e53280","DOI":"10.1371\/journal.pone.0053280","article-title":"Hearing loss and hair cell death in mice given the cholesterol-chelating agent hydroxypropyl-\u03b2-cyclodextrin","volume":"7","author":"Crumling","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114617_b0155","first-page":"391","article-title":"Effects of intracerebroventricular administration of 2-hydroxypropyl-\u03b2-cyclodextrin in a patient with Niemann-Pick Type C disease","volume":"1","author":"Matsuo","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.addr.2022.114617_b0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2017.12.014","article-title":"Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-\u03b2-Cyclodextrin","volume":"80","author":"Berry-Kravis","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.addr.2022.114617_b0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13023-019-1207-1","article-title":"Expanded access with intravenous hydroxypropyl-\u03b2-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis","volume":"14","author":"Hastings","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.addr.2022.114617_b0170","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/S0140-6736(17)31465-4","article-title":"Intrathecal 2-hydroxypropyl-\u03b2-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1\u20132 trial","volume":"390","author":"Ory","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2022.114617_b0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10162-015-0528-6","article-title":"Hearing Loss and Otopathology Following Systemic and Intracerebroventricular Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin","volume":"16","author":"Cronin","year":"2015","journal-title":"J. Assoc. Res. Otolaryngol."},{"key":"10.1016\/j.addr.2022.114617_b0180","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.277.5323.228","article-title":"Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis","volume":"277","author":"Carstea","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114617_b0185","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1126\/science.290.5500.2298","article-title":"Identification of HE1 as the second gene of Niemann-Pick C disease","volume":"290","author":"Naureckiene","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114617_b0190","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cell.2009.03.049","article-title":"Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol","volume":"137","author":"Kwon","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114617_b0195","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ymgme.2012.03.012","article-title":"NP-C Guidelines Working Group, Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update","volume":"106","author":"Patterson","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10545-014-9794-4","article-title":"Complex lipid trafficking in Niemann-Pick disease type C","volume":"38","author":"Vanier","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2022.114617_b0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0220","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","article-title":"Niemann-Pick disease type C","volume":"64","author":"Vanier","year":"2003","journal-title":"Clin. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0225","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ymgme.2021.06.011","article-title":"Estimating the prevalence of Niemann-Pick disease type C (NPC) in the United States","volume":"134","author":"Burton","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1248\/yakushi.21-00215","article-title":"Inclusion Solves Insolubility -Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C","volume":"142","author":"Irie","year":"2022","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.addr.2022.114617_b0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0024-3205(88)90150-6","article-title":"Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives","volume":"43","author":"Pitha","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2022.114617_b0240","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114617_b0245","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0024-3205(83)90304-1","article-title":"Rescue from hypervitaminosis A or potentiation of retinoid toxicity by different modes of cyclodextrin administration","volume":"32","author":"Pitha","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2022.114617_b0250","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0022-3476(87)80109-9","article-title":"Severe hypervitaminosis A in siblings: evidence of variable tolerance to retinol intake","volume":"111","author":"Carpenter","year":"1987","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2022.114617_b0255","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jps.2600810610","article-title":"Hydroxypropylcyclodextrins in parenteral use. II: Effects on transport and disposition of lipids in rabbit and humans","volume":"81","author":"Irie","year":"1992","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0024-3205(01)01384-4","article-title":"Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease","volume":"70","author":"Camargo","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2022.114617_b0265","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nm1073","article-title":"Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone","volume":"10","author":"Griffin","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2022.114617_b0270","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1194\/jlr.M700525-JLR200","article-title":"Genetic variations and treatments that affect the lifespan of the NPC1 mouse","volume":"49","author":"Liu","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2022.114617_b0275","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1073\/pnas.0810895106","article-title":"Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-\/- mouse","volume":"106","author":"Liu","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.addr.2022.114617_b0280","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/PDR.0b013e3181ee4dd2","article-title":"Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life","volume":"68","author":"Ramirez","year":"2010","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2022.114617_b0285","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1194\/jlr.M013789","article-title":"Quantitative role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by genetic and pharmacological manipulations","volume":"52","author":"Ramirez","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2022.114617_b0290","doi-asserted-by":"crossref","first-page":"e28418","DOI":"10.1371\/journal.pone.0028418","article-title":"Corneal alterations during combined therapy with cyclodextrin\/allopregnanolone and miglustat in a knock-out mouse model of NPC1 disease","volume":"6","author":"Hovakimyan","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114617_b0295","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1194\/jlr.M028241","article-title":"Cyclodextrin mediates rapid changes in lipid balance in Npc1-\/- mice without carrying cholesterol through the bloodstream","volume":"53","author":"Taylor","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2022.114617_b0300","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1093\/hmg\/dds322","article-title":"Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a \u03b2-cyclodextrin","volume":"21","author":"Maulik","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0305","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1093\/hmg\/dds193","article-title":"Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1","volume":"21","author":"Cluzeau","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0310","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.celrep.2013.10.042","article-title":"Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease","volume":"5","author":"Sarkar","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2022.114617_b0315","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2013.08.001","article-title":"Combined therapy with cyclodextrin\/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice","volume":"252","author":"Hovakimyan","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.addr.2022.114617_b0320","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1194\/jlr.M040618","article-title":"Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling","volume":"54","author":"Fan","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2022.114617_b0325","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2014.06.012","article-title":"A marked paucity of granule cells in the developing cerebellum of the Npc1(-\/-) mouse is corrected by a single injection of hydroxypropyl-\u03b2-cyclodextrin","volume":"70","author":"Nusca","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0330","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1074\/jbc.M113.526392","article-title":"Plasma signature of neurological disease in the monogenetic disorder Niemann-Pick Type C","volume":"289","author":"Alam","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0335","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13023-015-0348-0","article-title":"Visual evoked potentials of Niemann-Pick type C1 mice reveal an impairment of the visual pathway that is rescued by 2-hydroxypropyl-\u00df-cyclodextrin","volume":"10","author":"Palladino","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.addr.2022.114617_b0340","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jnr.23509","article-title":"Reduced cerebellar neurodegeneration after combined therapy with cyclodextrin\/allopregnanolone and miglustat in NPC1: a mouse model of Niemann-Pick type C1 disease","volume":"93","author":"Maass","year":"2015","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.addr.2022.114617_b0345","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40478-016-0370-z","article-title":"Developmental delay in motor skill acquisition in Niemann-Pick C1 mice reveals abnormal cerebellar morphogenesis","volume":"4","author":"Caporali","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"10.1016\/j.addr.2022.114617_b0350","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/jpet.116.232975","article-title":"Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease","volume":"358","author":"Bradbury","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2022.114617_b0355","doi-asserted-by":"crossref","first-page":"E777","DOI":"10.3390\/ijms18040777","article-title":"Increased Regenerative Capacity of the Olfactory Epithelium in Niemann-Pick Disease Type C1","volume":"18","author":"Meyer","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0360","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/hmg\/ddx118","article-title":"Shortened primary cilium length and dysregulated Sonic hedgehog signaling in Niemann-Pick C1 disease","volume":"26","author":"Canterini","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0365","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jnen\/nlx119","article-title":"LC3 Immunostaining in the Inferior Olivary Nuclei of Cats With Niemann-Pick Disease Type C1 Is Associated With Patterned Purkinje Cell Loss","volume":"77","author":"Gurda","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.addr.2022.114617_b0370","doi-asserted-by":"crossref","first-page":"E3563","DOI":"10.3390\/ijms19113563","article-title":"Main Olfactory and Vomeronasal Epithelium Are Differently Affected in Niemann-Pick Disease Type C1","volume":"19","author":"Witt","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0375","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ymgme.2018.10.009","article-title":"Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-\u03b2-cyclodextrin","volume":"125","author":"Cougnoux","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0380","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/hmg\/ddy112","article-title":"Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention","volume":"27","author":"Cougnoux","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0385","doi-asserted-by":"crossref","first-page":"E972","DOI":"10.3390\/ijms19040972","article-title":"Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemann-Pick-Disease Type C1","volume":"19","author":"Ebner","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0390","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13353-018-0431-z","article-title":"A pilot study of direct delivery of hydroxypropyl-beta-cyclodextrin to the lung by the nasal route in a mouse model of Niemann-Pick C1 disease: motor performance is unaltered and lung disease is worsened","volume":"59","author":"Erickson","year":"2018","journal-title":"J Appl Genet."},{"key":"10.1016\/j.addr.2022.114617_b0395","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gene.2017.12.006","article-title":"In Niemann-Pick C1 mouse models, glial-only expression of the normal gene extends survival much further than do changes in genetic background or treatment with hydroxypropyl-beta-cyclodextrin","volume":"643","author":"Marshall","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.addr.2022.114617_b0400","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12944-019-1088-2","article-title":"A therapy with miglustat, 2-hydroxypropyl-\u00df-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1","volume":"18","author":"Ne\u00dflauer","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.addr.2022.114617_b0405","doi-asserted-by":"crossref","first-page":"e2004735","DOI":"10.1002\/smll.202004735","article-title":"Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-\u03b2-cyclodextrin","volume":"16","author":"Carradori","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.addr.2022.114617_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2020.108725","article-title":"Delineation of metabolic responses of Npc1-\/-nih mice lacking the cholesterol-esterifying enzyme SOAT2 to acute treatment with 2-hydroxypropyl-\u03b2-cyclodextrin","volume":"164","author":"Ramirez","year":"2020","journal-title":"Steroids"},{"key":"10.1016\/j.addr.2022.114617_b0415","doi-asserted-by":"crossref","unstructured":"A. Gl\u00e4ser, F. Hammerl, M.H. Gr\u00e4ler, S.M. Coldewey, C. V\u00f6lkner, M.J. Frech, F. Yang, J. Luo, E. T\u00f6nnies, O. von Bohlen Und Halbach, N. Brandt, D. Heimes, A.-M. Ne\u00dflauer, G.C. Korenke, M. Owczarek-Lipska, J. Neidhardt, A. Rolfs, A. Wree, M. Witt, A.U. Br\u00e4uer, Identification of Brain-Specific Treatment Effects in NPC1 Disease by Focusing on Cellular and Molecular Changes of Sphingosine-1-Phosphate Metabolism, Int J Mol Sci. 21 (2020) E4502. 10.3390\/ijms21124502.","DOI":"10.3390\/ijms21124502"},{"key":"10.1016\/j.addr.2022.114617_b0420","doi-asserted-by":"crossref","first-page":"e0227829","DOI":"10.1371\/journal.pone.0227829","article-title":"Abnormal LAMP1 glycosylation may play a role in Niemann-Pick disease, type C pathology","volume":"15","author":"Cawley","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114617_b0425","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s10620-019-05736-x","article-title":"Ontogenesis and Modulation of Intestinal Unesterified Cholesterol Sequestration in a Mouse Model of Niemann-Pick C1 Disease","volume":"65","author":"Lopez","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0430","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.3390\/ijms22052539","article-title":"Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1","volume":"22","author":"Holzmann","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0435","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.devcel.2021.03.032","article-title":"Lipid-mediated motor-adaptor sequestration impairs axonal lysosome delivery leading to autophagic stress and dystrophy in Niemann-Pick type C","volume":"56","author":"Roney","year":"2021","journal-title":"Dev. Cell"},{"key":"10.1016\/j.addr.2022.114617_b0440","doi-asserted-by":"crossref","unstructured":"J.L. Rodriguez-Gil, L.L. Baxter, D.E. Watkins-Chow, N.L. Johnson, C.D. Davidson, S.R. Carlson, A.A. Incao, NISC Comparative Sequencing Program, K.L. Wallom, N.Y. Farhat, F.M. Platt, R.K. Dale, F.D. Porter, W.J. Pavan, Transcriptome of HP\u03b2CD-treated Niemann-pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics, Hum Mol Genet. (2021) ddab194. 10.1093\/hmg\/ddab194.","DOI":"10.1093\/hmg\/ddab194"},{"key":"10.1016\/j.addr.2022.114617_b0445","doi-asserted-by":"crossref","first-page":"e15054","DOI":"10.1371\/journal.pone.0015054","article-title":"Cyclodextrin induces calcium-dependent lysosomal exocytosis","volume":"5","author":"Chen","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114617_b0450","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11011-012-9332-8","article-title":"Amyloid-\u03b2 metabolism in Niemann-Pick C disease models and patients","volume":"27","author":"Mattsson","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.addr.2022.114617_b0455","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nbd.2013.12.018","article-title":"The autophagic defect in Niemann-Pick disease type C neurons differs from somatic cells and reduces neuronal viability","volume":"64","author":"Meske","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0460","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2014.10.006","article-title":"How to reduce the accumulation of autophagic vacuoles in NPC1-deficient neurons: a comparison of two pharmacological strategies","volume":"89","author":"Meske","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.addr.2022.114617_b0465","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1523\/JNEUROSCI.0900-16.2016","article-title":"Reversal of Pathologic Lipid Accumulation in NPC1-Deficient Neurons by Drug-Promoted Release of LAMP1-Coated Lamellar Inclusions","volume":"36","author":"Demais","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2022.114617_b0470","doi-asserted-by":"crossref","first-page":"31750","DOI":"10.1038\/srep31750","article-title":"PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder","volume":"6","author":"Brown","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114617_b0475","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1021\/acs.jproteome.7b00070","article-title":"Impact of the Niemann-Pick c1 Gene Mutation on the Total Cellular Glycomics of CHO Cells","volume":"16","author":"Furukawa","year":"2017","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.addr.2022.114617_b0480","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/jimd.12210","article-title":"Nanoparticles containing \u03b2-cyclodextrin potentially useful for the treatment of Niemann-Pick C","volume":"43","author":"Donida","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0485","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1194\/jlr.RA119000571","article-title":"Monitoring the itinerary of lysosomal cholesterol in Niemann-Pick Type C1-deficient cells after cyclodextrin treatment","volume":"61","author":"Feltes","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2022.114617_b0490","doi-asserted-by":"crossref","unstructured":"P. Av, K. I, D.P. R, W. Ca, F. H, K. P, J. X, O. Ds, B. Js, W. Me, P. Fd, A human iPSC-derived inducible neuronal model of Niemann-Pick disease, type C1, BMC Biology. 19 (2021). 10.1186\/s12915-021-01133-x.","DOI":"10.1186\/s12915-021-01133-x"},{"key":"10.1016\/j.addr.2022.114617_b0495","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.b14-00726","article-title":"Efficacy of 2-Hydroxypropyl-\u03b2-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease","volume":"38","author":"Tanaka","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2022.114617_b0500","doi-asserted-by":"crossref","first-page":"E452","DOI":"10.3390\/ijms22010452","article-title":"Intracerebroventricular Treatment with 2-Hydroxypropyl-\u03b2-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice","volume":"22","author":"Fukaura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0505","unstructured":"FDA Cyclodextrin Filings | The Addi and Cassi Fund - Niemann Pick Type C, (n.d.). http:\/\/addiandcassi.com\/category\/cyclodextrin\/fda-cyclodextrin-filings\/ (accessed November 7, 2021)."},{"key":"10.1016\/j.addr.2022.114617_b0510","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ymgme.2016.04.014","article-title":"In vitro evaluation of 2-hydroxyalkylated \u03b2-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease","volume":"118","author":"Kondo","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0515","article-title":"A phase 1\/2 open label nonrandomized clinical trial of intravenous 2-hydroxypropyl-\u03b2-cyclodextrin for acute liver disease in infants with Niemann-Pick C1","volume":"28","author":"Reynolds","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.addr.2022.114617_b0520","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ymgme.2020.11.005","article-title":"Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1","volume":"131","author":"Sidhu","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0525","unstructured":"Cyclo Therapeutics, Inc., An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol\u00ae Cyclo (HP-\u03b2-CD) in Patients With Niemann-Pick Disease Type C (NPC-1), clinicaltrials.gov, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03893071 (accessed November 4, 2021)."},{"key":"10.1016\/j.addr.2022.114617_b0530","unstructured":"Cyclo Therapeutics, Inc., Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg\/kg of Trappsol\u00aeCycloTM (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC), clinicaltrials.gov, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04860960 (accessed November 4, 2021)."},{"key":"10.1016\/j.addr.2022.114617_b0535","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jns.2015.08.719","article-title":"Intrathecal 2-Hydroxypropyl-Beta-Cyclodextrin (HPBCD) therapy in adult-onset Niemann-Pick Disease Type C (NPC)","volume":"357","author":"Sakiyama","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0540","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymgme.2015.07.001","article-title":"Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1","volume":"116","author":"Maarup","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114617_b0545","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10072-017-2833-9","article-title":"Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases","volume":"38","author":"Meg\u00edas-Vericat","year":"2017","journal-title":"Neurol Sci."},{"key":"10.1016\/j.addr.2022.114617_b0550","unstructured":"Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company, Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease, clinicaltrials.gov, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01747135 (accessed November 4, 2021)."},{"key":"10.1016\/j.addr.2022.114617_b0555","unstructured":"Mandos LLC, A Phase 2b\/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of VTS-270 (2-hydroxypropyl-\u03b2-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease, clinicaltrials.gov, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02534844 (accessed November 4, 2021)."},{"key":"10.1016\/j.addr.2022.114617_b0560","unstructured":"NNPDF \u2013 Turning the Impossible, Into Possible, (n.d.). https:\/\/nnpdf.org\/ (accessed November 16, 2021)."},{"key":"10.1016\/j.addr.2022.114617_b0565","doi-asserted-by":"crossref","first-page":"E898","DOI":"10.3390\/ijms21030898","article-title":"Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in Npc1-Null Cells","volume":"21","author":"Hoque","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0570","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1074\/jbc.M111.326405","article-title":"Normalization of cholesterol homeostasis by 2-hydroxypropyl-\u03b2-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice","volume":"287","author":"Peake","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0575","first-page":"19","article-title":"Influence of Npc1 genotype on the toxicity of hydroxypropyl-\u03b2-cyclodextrin, a potentially therapeutic agent","volume":"1","author":"Tanaka","year":"2014","journal-title":"Niemann-Pick Type C disease models, Mol Genet Metab Rep."},{"key":"10.1016\/j.addr.2022.114617_b0580","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1111\/bph.15464","article-title":"Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C","volume":"178","author":"Yamada","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2022.114617_b0585","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1248\/bpb.26.424","article-title":"Oxidative stress in early stage of acute lung injury induced with oleic acid in guinea pigs","volume":"26","author":"Yang","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2022.114617_b0590","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1211\/0022357023150","article-title":"Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs","volume":"56","author":"Ishitsuka","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114617_b0595","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1248\/bpb.27.1451","article-title":"Preventive effect of tranilast on oleic acid-induced lung injury in guinea pigs","volume":"27","author":"Ishitsuka","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2022.114617_b0600","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1254\/jphs.09128SC","article-title":"A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs","volume":"111","author":"Ishitsuka","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0605","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1248\/bpb.32.500","article-title":"Effects of bolus injection of soybean-based fat emulsion and fatty acids on pulmonary gas exchange function","volume":"32","author":"Ishitsuka","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2022.114617_b0610","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1211\/jpp.61.07.0012","article-title":"Protection afforded by a herbal medicine, Sho-seiryu-to (TJ-19), against oleic acid-induced acute lung injury in guinea-pigs","volume":"61","author":"Yang","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114617_b0615","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/jps.2600830615","article-title":"Parenteral hydroxypropyl cyclodextrins: intravenous and intracerebral administration of lipophiles","volume":"83","author":"Pitha","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0620","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/js960075u","article-title":"Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery","volume":"85","author":"Rajewski","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0625","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","article-title":"2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review","volume":"43","author":"Gould","year":"2005","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.addr.2022.114617_b0630","unstructured":"Deaf or Death? In Drug Trial, Parents Weigh Life vs. Hearing Loss - WSJ, (n.d.). https:\/\/www.wsj.com\/articles\/deaf-or-death-in-drug-trial-parents-weigh-life-vs-hearing-loss-1425267002 (accessed November 7, 2021)."},{"key":"10.1016\/j.addr.2022.114617_b0635","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajmg.b.30969","article-title":"Linear clinical progression, independent of age of onset, Niemann-Pick disease, type C","volume":"153B","author":"Yanjanin","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"key":"10.1016\/j.addr.2022.114617_b0640","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/acn3.306","article-title":"Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease","volume":"3","author":"Davidson","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.addr.2022.114617_b0645","doi-asserted-by":"crossref","first-page":"e0175236","DOI":"10.1371\/journal.pone.0175236","article-title":"Direct administration of 2-Hydroxypropyl-Beta-Cyclodextrin into guinea pig cochleae: Effects on physiological and histological measurements","volume":"12","author":"Lichtenhan","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114617_b0650","first-page":"69","article-title":"Ebselen","volume":"23","author":"Lee","year":"2019","journal-title":"Has No Preventive Effect in New Hearing Loss Model Using a Cholesterol-Chelating Agent, J Audiol Otol."},{"key":"10.1016\/j.addr.2022.114617_b0655","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12640-020-00252-7","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin Ototoxicity in Adult Rats: Rapid Onset and Massive Destruction of Both Inner and Outer Hair Cells Above a Critical Dose","volume":"38","author":"Liu","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.addr.2022.114617_b0660","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.643709","article-title":"Spatiotemporal Developmental Upregulation of Prestin Correlates With the Severity and Location of Cyclodextrin-Induced Outer Hair Cell Loss and Hearing Loss","volume":"9","author":"Ding","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2022.114617_b0665","doi-asserted-by":"crossref","first-page":"21973","DOI":"10.1038\/srep21973","article-title":"Susceptibility of outer hair cells to cholesterol chelator 2-hydroxypropyl-\u03b2-cyclodextrine is prestin-dependent","volume":"6","author":"Takahashi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114617_b0670","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40478-018-0599-9","article-title":"The susceptibility of cochlear outer hair cells to cyclodextrin is not related to their electromotile activity","volume":"6","author":"Zhou","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"10.1016\/j.addr.2022.114617_b0675","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fncel.2017.00355","article-title":"Cyclodextrins and Iatrogenic Hearing Loss: New Drugs with Significant Risk","volume":"11","author":"Crumling","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.addr.2022.114617_b0680","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1749-6632.1991.tb19618.x","article-title":"Audiologic profile in Niemann-Pick C","volume":"630","author":"Pikus","year":"1991","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0685","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/AUD.0b013e3182a362b8","article-title":"Auditory phenotype of Niemann-Pick disease, type C1","volume":"35","author":"King","year":"2014","journal-title":"Ear Hear."},{"key":"10.1016\/j.addr.2022.114617_b0690","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/stem.1917","article-title":"HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells","volume":"33","author":"Soga","year":"2015","journal-title":"Stem Cells."},{"key":"10.1016\/j.addr.2022.114617_b0695","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1021\/acs.jpcb.8b02098","article-title":"Predicting the Binding Mode of 2-Hydroxypropyl-\u03b2-cyclodextrin to Cholesterol by Means of the MD Simulation and the 3D-RISM-KH Theory","volume":"122","author":"Hayashino","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.addr.2022.114617_b0700","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1432-1033.1989.tb15171.x","article-title":"Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes","volume":"186","author":"Ohtani","year":"1989","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.addr.2022.114617_b0705","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10847-008-9510-9","article-title":"Study of the cholesterol extraction capacity of \u03b2-cyclodextrin and its derivatives, relationships with their effects on endothelial cell viability and on membrane models","volume":"63","author":"Castagne","year":"2009","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0710","doi-asserted-by":"crossref","first-page":"e1002020","DOI":"10.1371\/journal.pcbi.1002020","article-title":"Molecular mechanism of cyclodextrin mediated cholesterol extraction","volume":"7","author":"L\u00f3pez","year":"2011","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.addr.2022.114617_b0715","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2017.1329081","article-title":"Methyl-\u03b2-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK","volume":"13","author":"Dai","year":"2017","journal-title":"Autophagy."},{"key":"10.1016\/j.addr.2022.114617_b0720","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1523\/JNEUROSCI.0782-16.2016","article-title":"Noise-Induced Loss of Hair Cells and Cochlear Synaptopathy Are Mediated by the Activation of AMPK","volume":"36","author":"Hill","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2022.114617_b0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-1056-1","article-title":"Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1","volume":"9","author":"Singhal","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2022.114617_b0730","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1038\/s41598-020-65627-4","article-title":"2-Hydroxypropyl-gamma-cyclodextrin overcomes NPC1 deficiency by enhancing lysosome-ER association and autophagy","volume":"10","author":"Singhal","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114617_b0735","doi-asserted-by":"crossref","first-page":"E1228","DOI":"10.3390\/molecules23051228","article-title":"Cyclodextrins: Assessing the Impact of Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol Homeostasis","volume":"23","author":"Szente","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2022.114617_b0740","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.carres.2017.11.003","article-title":"Role of 6-O-\u03b1-maltosyl-\u03b2-cyclodextrin in lysosomal cholesterol deprivation in Npc1-deficient Chinese hamster ovary cells","volume":"455","author":"Okada","year":"2018","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.addr.2022.114617_b0745","doi-asserted-by":"crossref","first-page":"E1152","DOI":"10.3390\/ijms20051152","article-title":"In Vitro and In Vivo Evaluation of 6-O-\u03b1-Maltosyl-\u03b2-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C","volume":"20","author":"Yasmin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114617_b0750","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0378-5173(89)90116-6","article-title":"Some physicochemical properties of branched \u03b2-cyclodextrins and their inclusion characteristics","volume":"49","author":"Yamamoto","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114617_b0755","doi-asserted-by":"crossref","unstructured":"K. Karashima, M. Taniguchi, T. Nakamura, M. Takasaki, K. Matsuo, M. Irikura, T. Irie, Prolongation of intrathecal and sciatic nerve blocks using a complex of levobupivacaine with maltosyl-beta-cyclodextrin in rats, Anesth Analg. 104 (2007) 1121\u20131128, tables of contents. 10.1213\/01.ane.0000260309.15034.52.","DOI":"10.1213\/01.ane.0000260309.15034.52"},{"key":"10.1016\/j.addr.2022.114617_b0760","doi-asserted-by":"crossref","first-page":"e0175478","DOI":"10.1371\/journal.pone.0175478","article-title":"Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1","volume":"12","author":"Yergey","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114617_b0765","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1021\/cr970019t","article-title":"NMR Studies of Cyclodextrins and Cyclodextrin Complexes","volume":"98","author":"Schneider","year":"1998","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2022.114617_b0770","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3762\/bjoc.11.224","article-title":"Cholesterol lowering effects of mono-lactose-appended \u03b2-cyclodextrin in Niemann-Pick type C disease-like HepG2 cells","volume":"11","author":"Motoyama","year":"2015","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0775","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3762\/bjoc.13.2","article-title":"Synthesis of multi-lactose-appended \u03b2-cyclodextrin and its cholesterol-lowering effects in Niemann-Pick type C disease-like HepG2 cells","volume":"13","author":"Motoyama","year":"2017","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0780","doi-asserted-by":"crossref","first-page":"E802","DOI":"10.3390\/nano9050802","article-title":"In vivo Efficacy and Safety Evaluation of Lactosyl-\u03b2-cyclodextrin as a Therapeutic Agent for Hepatomegaly in Niemann-Pick Type C Disease","volume":"9","author":"Maeda","year":"2019","journal-title":"Nanomaterials (Basel)."},{"key":"10.1016\/j.addr.2022.114617_b0785","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jconrel.2020.09.043","article-title":"Lactose-appended \u03b2-cyclodextrin as an effective nanocarrier for brain delivery","volume":"328","author":"Yokoyama","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114617_b0790","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1038\/srep04356","article-title":"Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating Niemann-Pick type C disease","volume":"4","author":"Tamura","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114617_b0795","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1074\/jbc.M115.636803","article-title":"\u03b2-Cyclodextrin-threaded biocleavable polyrotaxanes ameliorate impaired autophagic flux in Niemann-Pick type C disease","volume":"290","author":"Tamura","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0800","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/14686996.2016.1200948","article-title":"Lysosomal pH-inducible supramolecular dissociation of polyrotaxanes possessing acid-labile N-triphenylmethyl end groups and their therapeutic potential for Niemann-Pick type C disease","volume":"17","author":"Tamura","year":"2016","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.addr.2022.114617_b0805","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2017.11.016","article-title":"Polyrotaxane-based systemic delivery of \u03b2-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease","volume":"269","author":"Tamura","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114617_b0810","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1038\/s41598-018-27926-9","article-title":"Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder","volume":"8","author":"Kulkarni","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114617_b0815","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2019.12.021","article-title":"Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity","volume":"319","author":"Kim","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114617_b0820","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10545-007-0632-9","article-title":"The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease","volume":"30","author":"Schuchman","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114617_b0825","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.5966\/sctm.2015-0373","article-title":"Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A","volume":"5","author":"Long","year":"2016","journal-title":"Stem Cells Transl Med."},{"key":"10.1016\/j.addr.2022.114617_b0830","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jphp.12405","article-title":"Effects of cyclodextrins on GM1-gangliosides in fibroblasts from GM1-gangliosidosis patients","volume":"67","author":"Maeda","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114617_b0835","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10847-018-0835-8","article-title":"Lowering effect of dimethyl-\u03b1-cyclodextrin on GM1-ganglioside accumulation in GM1-gangliosidosis model cells and in brain of \u03b2-galactosidase-knockout mice","volume":"93","author":"Maeda","year":"2019","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0840","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","article-title":"Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis","volume":"33","author":"Sandhoff","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2022.114617_b0845","series-title":"Beta-galactosidase deficiency (beta-galactosidosis): GM1 gangliosidosis and Morquio B disease","author":"Suzuki","year":"2001"},{"key":"10.1016\/j.addr.2022.114617_b0850","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1093\/hmg\/ddv153","article-title":"BCM-95 and (2-hydroxypropyl)-\u03b2-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in Sap C-deficient fibroblasts","volume":"24","author":"Tatti","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2022.114617_b0855","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-017-0670-9","article-title":"Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics","volume":"12","author":"Aguisanda","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.addr.2022.114617_b0860","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1039\/C3OB42530D","article-title":"Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier","volume":"12","author":"Rodr\u00edguez-Lavado","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.addr.2022.114617_b0865","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejpb.2015.02.002","article-title":"Enhanced delivery of daidzein into fibroblasts and neuronal cells with cationic derivatives of gamma-cyclodextrin for the control of cellular glycosaminoglycans","volume":"91","author":"Kami\u0144ski","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22005075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22005075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:24:52Z","timestamp":1777515892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22005075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":173,"alternative-id":["S0169409X22005075"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114617","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclodextrins applied to the treatment of lysosomal storage disorders","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114617"}}